Los Angeles Capital Management’s Neurocrine Biosciences NBIX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $34.3M | Buy |
203,548
+54,437
| +37% | +$8.08M | 0.13% | 158 |
|
|
2026
Q1 | $19.6M | Sell |
149,111
-1,142,167
| -88% | -$152M | 0.08% | 187 |
|
|
2025
Q4 | $178M | Buy |
1,291,278
+88,522
| +7% | +$12.8M | 0.61% | 33 |
|
|
2025
Q3 | $169M | Buy |
1,202,756
+458,106
| +62% | +$62.1M | 0.57% | 33 |
|
|
2025
Q2 | $93.6M | Buy |
744,650
+740,842
| +19,455% | +$85M | 0.35% | 61 |
|
|
2025
Q1 | $421K | Sell |
3,808
-509,012
| -99% | -$64.5M | ﹤0.01% | 793 |
|
|
2024
Q4 | $70M | Buy |
512,820
+92,072
| +22% | +$11.4M | 0.28% | 74 |
|
|
2024
Q3 | $48.5M | Buy |
420,748
+363,863
| +640% | +$49.9M | 0.2% | 104 |
|
|
2024
Q2 | $7.83M | Sell |
56,885
-188,496
| -77% | -$25.8M | 0.03% | 288 |
|
|
2024
Q1 | $33.8M | Sell |
245,381
-673,010
| -73% | -$91.9M | 0.12% | 160 |
|
|
2023
Q4 | $121M | Buy |
918,391
+364,986
| +66% | +$42M | 0.45% | 52 |
|
|
2023
Q3 | $62.3M | Buy |
553,405
+2,807
| +0.5% | +$296K | 0.26% | 78 |
|
|
2023
Q2 | $51.9M | Sell |
550,598
-84,247
| -13% | -$8.23M | 0.21% | 98 |
|
|
2023
Q1 | $64.3M | Sell |
634,845
-128,847
| -17% | -$13.4M | 0.29% | 82 |
|
|
2022
Q4 | $91.2M | Sell |
763,692
-28,274
| -4% | -$3.31M | 0.44% | 56 |
|
|
2022
Q3 | $84.1M | Buy |
+791,966
| New | +$80.4M | 0.44% | 51 |
|
|
2021
Q4 | – | Sell |
-14,016
| Closed | -$1.34M | – | 1449 |
|
|
2021
Q3 | $1.34M | Sell |
14,016
-5,177
| -27% | -$489K | 0.01% | 651 |
|
|
2021
Q2 | $1.87M | Sell |
19,193
-36,255
| -65% | -$3.48M | 0.01% | 601 |
|
|
2021
Q1 | $5.39M | Sell |
55,448
-90,189
| -62% | -$9.46M | 0.02% | 397 |
|
|
2020
Q4 | $14M | Sell |
145,637
-31,120
| -18% | -$3.01M | 0.06% | 227 |
|
|
2020
Q3 | $17M | Buy |
176,757
+43,631
| +33% | +$5.05M | 0.08% | 186 |
|
|
2020
Q2 | $16.2M | Buy |
133,126
+122,431
| +1,145% | +$13.5M | 0.08% | 205 |
|
|
2020
Q1 | $926K | Buy |
10,695
+2,395
| +29% | +$234K | 0.01% | 732 |
|
|
2019
Q4 | $892K | Buy |
8,300
+4,730
| +132% | +$495K | ﹤0.01% | 871 |
|
|
2019
Q3 | $322K | Sell |
3,570
-14,380
| -80% | -$1.34M | ﹤0.01% | 1110 |
|
|
2019
Q2 | $1.52M | Sell |
17,950
-7,060
| -28% | -$580K | 0.01% | 713 |
|
|
2019
Q1 | $2.2M | Buy |
25,010
+21,040
| +530% | +$1.76M | 0.01% | 631 |
|
|
2018
Q4 | $283K | Buy |
3,970
+1,880
| +90% | +$180K | ﹤0.01% | 1124 |
|
|
2018
Q3 | $257K | Sell |
2,090
-3,570
| -63% | -$405K | ﹤0.01% | 1269 |
|
|
2018
Q2 | $556K | Sell |
5,660
-2,410
| -30% | -$216K | ﹤0.01% | 1105 |
|
|
2018
Q1 | $669K | Buy |
+8,070
| New | +$681K | ﹤0.01% | 945 |
|
Other funds holding NBIX
Los Angeles Capital Management's NBIX Position: Q2 2026 in Review
Los Angeles Capital Management increased its Neurocrine Biosciences (NBIX) stake by 37% in Q2 2026, buying an estimated $8.08M and bringing the position to 203,548 shares worth $34.3M. The position accounts for 0.13% of the portfolio, ranked #158.
Los Angeles Capital Management first reported a position in NBIX in Q1 2018 and has held it in 31 quarters since. The position peaked at $178M in Q4 2025. 781 funds tracked by Wall St. Rank hold NBIX as of Q2 2026.
- Los Angeles Capital Management held 203,548 shares of Neurocrine Biosciences worth $34.3M as of Q2 2026.
- Los Angeles Capital Management bought 54,437 Neurocrine Biosciences shares in Q2 2026, an estimated $8.08M.
- Neurocrine Biosciences made up 0.13% of Los Angeles Capital Management's portfolio in Q2 2026, its #158 holding.
- Los Angeles Capital Management first reported a position in Neurocrine Biosciences in Q1 2018 and has held it in 31 quarters since.
- Los Angeles Capital Management's Neurocrine Biosciences position peaked at $178M in Q4 2025.
- 781 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q2 2026.
Based on Los Angeles Capital Management's 13F filing for Q2 2026, filed 13 Aug 2026.